{"filing":{"accession_number":"0001213900-26-087226","cik":"0001614744","ticker":"PPBT","company_name":"PURPLE BIOTECH LTD.","form":"6-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"ea0301142-6k_purple.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1614744/000121390026087226/ea0301142-6k_purple.htm"},"events":[{"id":26513,"run_id":24099,"accession_number":"0001213900-26-087226","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This is a corporate presentation detailing Purple Biotech's CAPTN-3 tri-specific antibody platform and pipeline progress, including preclinical data for lead program IM1240 and second program IM1305. The exhibit discloses material operational and strategic milestones: completion of non-human primate toxicology studies, IND submission planned for 2027, Phase 1 initiation expected in H1 2027, and a pre-IND meeting with a clear development roadmap. These represent significant operational progress toward clinical development of novel oncology therapeutics, constituting a material business update on product development strategy and near-term catalysts.","company_name":"PURPLE BIOTECH LTD.","ticker":"PPBT","filing_date":"2026-08-10","form":"6-K","submitted_at":null,"items":[{"id":27665,"accession_number":"0001213900-26-087226","item_number":"EX-99.1","item_title":"ea030114201ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This is a corporate presentation detailing Purple Biotech's CAPTN-3 tri-specific antibody platform and pipeline progress, including preclinical data for lead program IM1240 and second program IM1305. The exhibit discloses material operational and strategic milestones: completion of non-human primate toxicology studies, IND submission planned for 2027, Phase 1 initiation expected in H1 2027, and a pre-IND meeting with a clear development roadmap. These represent significant operational progress toward clinical development of novel oncology therapeutics, constituting a material business update on product development strategy and near-term catalysts.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:07:01.637922+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27665,"accession_number":"0001213900-26-087226","item_number":"EX-99.1","item_title":"ea030114201ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This is a corporate presentation detailing Purple Biotech's CAPTN-3 tri-specific antibody platform and pipeline progress, including preclinical data for lead program IM1240 and second program IM1305. The exhibit discloses material operational and strategic milestones: completion of non-human primate toxicology studies, IND submission planned for 2027, Phase 1 initiation expected in H1 2027, and a pre-IND meeting with a clear development roadmap. These represent significant operational progress toward clinical development of novel oncology therapeutics, constituting a material business update on product development strategy and near-term catalysts.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:07:01.637922+00:00","company_name":"PURPLE BIOTECH LTD.","ticker":"PPBT","filing_date":"2026-08-10"}]}